Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2020
Sick of high drug prices, insurers join hospitals to make their own generic medications
23 January 2020 - Everyone complains about high drug prices. But hospitals — and now insurers — are trying to ...
Posted by Michael Wonder on 22 Jan 2020
Supporting innovative medicines funding in Scotland
21 January 2020 - Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure ...
Posted by Michael Wonder on 22 Jan 2020
Parents demanding PHARMAC funding boost unleash on politicians at Parliament steps
22 January 2020 - The parents of a daughter with cystic fibrosis have cycled 1300 km from Dunedin to Wellington ...
Posted by Michael Wonder on 22 Jan 2020
Amazon just filed a bunch of international trademarks for ‘Amazon Pharmacy’
21 January 2020 - Amazon bought an Internet pharmacy business called PillPack in 2018. ...
Posted by Michael Wonder on 21 Jan 2020
FDA approves first treatment for thyroid eye disease
21 January 2020 - Today, the U.S. FDA approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a ...
Posted by Michael Wonder on 21 Jan 2020
Old drug, new tricks: existing medicines show promise in fighting cancer
20 January 2020 - Dozens of compounds approved for other purposes can kill cancer cells selectively. ...
Posted by Michael Wonder on 21 Jan 2020
Genprex receives U.S. FDA fast track designation for gene therapy that targets lung cancer
21 January 2020 - Genprex today announced that the U.S FDA has granted fast track Designation for Genprex’s Oncoprex immunogene ...
Posted by Michael Wonder on 21 Jan 2020
US FDA grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
21 January 2020 - Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients. ...
Posted by Michael Wonder on 21 Jan 2020
Achieving cost savings with biosimilars will require new strategies, authors say
20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...
Posted by Michael Wonder on 21 Jan 2020
The biosimilar solution to expensive cancer care
20 January 2020 - In a recent column in Evidence-Based Oncology, Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer ...
Posted by Michael Wonder on 21 Jan 2020
Pharma says price regulation will take life saving drugs away from us, but here’s the truth
21 January 2020 - The US isn’t the only country struggling with the high price of prescription drugs. A decade ...
Posted by Michael Wonder on 21 Jan 2020
Will the FDA give the go-ahead to a prescription video game? The wait goes on, as new data come in.
21 January 2020 - In mid 2018, the startup Akili Interactive Labs asked the Food and Drug Administration to let ...
Posted by Michael Wonder on 21 Jan 2020
Mum says 'miracle' drug saved ill baby Kaan Hunter's life
21 January 2020 - A baby who was given only four months to live after being diagnosed with an extremely ...
Posted by Michael Wonder on 21 Jan 2020
European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma
21 January 2020 - Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b. ...
Posted by Michael Wonder on 21 Jan 2020
Health gap fees up to 10 times higher in northern Sydney than elsewhere in NSW
21 January 2020 - Private health insurance gap fees are up to 10 times larger in northern Sydney than elsewhere ...
Posted by Michael Wonder on 21 Jan 2020
Janssen seeks expanded use of Imbruvica (ibrutinib) in combination with rituximab for patients with previously untreated chronic lymphocytic leukaemia
20 January 2020 - Application supported by the Phase 3 E1912 study evaluating the use of ibrutinib in combination with rituximab, ...